Argenx Se · EURONEXT:ARGX
Argenx — Investor Presentation (March 2026)
25 slides from Argenx's investor presentation, March 2026
Slide 1: Leading a new era of innovation in immunology
Leading a new era of innovation in immunology C O R P O R AT E P R E S E N TAT I O N M a r c h 2 0 2 6 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: Connecting Science and Patients to Unlock Infinite Opportunity
Connecting Science and Patients to Unlock Infinite Opportunity Science Patients 3
Slide 4: Advancing Vision 2030
Advancing Vision 2030 Execution in 2025 VISION 2030 ~19K Patients Treated Globally* 50 K Patients on Treatment 10 Ongoing Registrational Studies 10 Labeled Indications Michele, CIDP Patient 4 New Molecules Entered Pipeline 5 New Molecules in Phase 3 4
Slide 5: Product Net Sales of $1.3 billion in Q4
Product Net Sales of $1.3 billion in Q4 1,286 Product Net Sales by Quarter Q4 2025: growth of 74% vs Q4 2024 $’m 1,127 YoY % China (in millions of $) Q4 2025 Q4 2024 Growth Growth * RoW US 1,087 649 438 68% Japan 949 Japan 63 27 36 134% US 790 RoW 110 49 61 108% 737 China supply 26 12 14 113% Total
Slide 6: 2026 Strategic Priorities
2026 Strategic Priorities Impact More Patients Shape Long-Term Deliver Next Wave with VYVGART Future of FcRn of Innovation Deliver broadest MG label First empa Phase 3 readout Advance combination (MMN) approaches AIM and ITP Phase 3 readouts 4 Phase 3 molecules 3 Clinical-stage FcRn Expand into rheu
Slide 7: Playbook to Reach 50k More Patients: Impact Patients with VYVGART
Playbook to Reach 50kMore Impact Patients Patients with VYVGART 7
Slide 8: Prefilled Syringe Launch is Increasing Patient Impact and Broadening Prescriber Base
Prefilled Syringe Launch is Increasing Patient Impact and Broadening Prescriber Base #1 PRESCRIBED BIOLOGIC MG EXPANSION VYVGART drove 70% Patients directly from orals 60% Growth in overall MG biologics share Earlier Line Patients NEW PRESCRIBER CIDP EXPANSION AND PATIENT GROWTH Achieved >4,700 Pre
Slide 9: Building Durable Leadership with the Broadest Label in MG
Building Durable Leadership with the Broadest Label in MG U.S. Addressable MG Patients +25K Redefine Patient Outcomes Launch in Seronegative MG* +7K Limited current treatment options Growth in Ocular MG Phase 3 Readout +11K Biologics Share of Market 60K ADAPT-OCULUS registrational study met primary
Slide 10: Positive Ocular MG Data Support MG Label Expansion
Positive Ocular MG Data Support MG Label Expansion ADAPT-OCULUS* 0 -0.5 Mean Change from BL in MGII (PRO) Ocular -1 -1.5 -2 First registrational study in oMG -2.5 -3 Study met primary endpoint (p=0.012) -3.5 2.05-point placebo-adjusted -4 improvement in MGII PRO -4.5 No new safety concerns identifie
Slide 11: Data Support Broadest Label in MG
Data Support Broadest Label in MG ADAPT* ADAPT-SERON* ADAPT-OCULUS* 0 0 0 Mean Change from BL in MGII (PRO) Ocular -0.5 -0.5 -0.5 Mean Change from BL in MG-ADL Mean Change from BL in MG-ADL -1 -1 -1 -1.5 -1.5 -1.5 -2 -2 -2 -2.5 -2.5 -2.5 -3 -3 -3 -3.5 -3.5 -3.5 -4 -4 -4 -4.5 -4.5 -4.5 -5 -5 -5 BL W1
Slide 12: Roadmap to CIDP Market Expansion
Roadmap to CIDP Market Expansion Redefine Treatment Evidence Generation ADHERE+ Functional Benefit HCP Prescriber Growth 42K Redefine Patient Outcomes 24K Biomarker Exploration IgG, IgM Autoantibodies 12K Progressing Multiple MOAs Addressable Total Treated Total Diagnosed Co-positioning VYVGART & Em
Slide 13: Building our Presence in Rheumatology
Building our Presence in Rheumatology Autoimmune Myositis Sjögren’s Disease PM Redefining Biology 10K MSAs1 linked to disease severity in IMNM; skin rash and treatment Anti-Ro/SSA and Anti-La/SSB IMNM response in DM are hallmarks of disease 20K 230K Redefining Treatment 70K Phase 2: Significant impr
Slide 14: Playbook to Reach 50k Patients: Shape Long-term Future of FcRn
Playbook to Reach 50kthe Shape Patients Long-term Future of FcRn 14
Slide 15: Building a Sustainable FcRn Franchise
Building a Sustainable FcRn Franchise Diversified FcRn portfolio elevating the patient experience across IgG-mediated diseases Today Tomorrow Differentiated Efficacy and Patient Experience Enduring FcRn Leadership ARGX-213 ARGX-124 ARGX-XXX Phase 3 ready Phase 1 Future molecules FcRn Optimizing pati
Slide 16: Playbook to Reach 50k Patients: Deliver Next Wave of Innovation
Playbook to Reach 50k Patients Deliver Next Wave of Innovation 16
Slide 17: This will be a Pivotal Year for empasiprubart with First Phase 3 Readout in MMN
This will be a Pivotal Year for empasiprubart with First Phase 3 Readout in MMN 12k patients Market in MMN expected to grow MMN across key markets beyond $1B by 2030 Unmet Need 40% 0 60% Initially Targeted Progression misdiagnosed treatments despite treatment Future $1B+ Today Disease Burden $750-80
Slide 18: Empasiprubart Sustained Improved Grip Strength in MMN
Empasiprubart Sustained Improved Grip Strength in MMN ARDA Phase 2 ARDA+ Open Label Grip strength change from baseline (kPA) 18
Slide 19: Transformative Potential Across Pipeline Programs
Transformative Potential Across Pipeline Programs Efgartigimod Empasiprubart Adimanebart ARGX-213 ARGX-121 First-in-class Potent C2 MuSK agonist FcRn: Sustained IgA Sweeping Fc Fragment antibody antibody IgG reduction Antibody 15+ 3+ 2+ 15+ 3+ Indications Indications Indications Potential indication
Slide 20: Successfully Advancing Next Wave of Molecules
Successfully Advancing Next Wave of Molecules ARGX-213: Convenient Monthly Dose Achieved ARGX-121: Human Data Show Rapid and Total in Humans IgA Depletion IgG Change from baseline (%) IgA Change from baseline (%) IgA-targeting Fc-ABDEGTM Fab α-albumin Fc-ABDEGTM VHH 20
Slide 21: Three New Phase 1 Molecules in 2026
Three New Phase 1 Molecules in 2026 Expanding our Academic Research Centers Biopharma companies ecosystem of where we Immunology Labs Immunology pipelines source novel biology g erin gy e iolo B Nov ion in Pip roduct ap el P elin Innovation e Engine An B e tib st in Field ring ody Enginee Broadened
Slide 22: Innovation Model Generating World-Class Pipeline
Innovation Model Generating World-Class Pipeline IIP/Preclinical Phase 1 PoC Registrational Approved ARGX-118 (Galectin) AMR Seronegative ARGX-124 (FcRn) Scleroderma Ocular MG 25 ARGX-125 AIE ITP Active IIP TSP-101 (Fn14) DGF Graves’ Disease PROGRAMS programs SMA Sjogren’s Disease Other Spanning neu
Slide 23: 6 Registrational Readouts Over Next 24 Months
6 Registrational Readouts Over Next 24 Months Phase 3 Data Readouts EFGARTIGIMOD EMPASIPRUBART Myositis 3Q 2026 MMN 4Q 2026 ITP 4Q 2026 CIDP 2H 2027 Sjogren’s Disease 2H 2027 Decision on Approval AChR- gMG (MuSK+, LRP4+, triple seronegative) PDUFA date of May 10, 2026 23
Slide 24: Attractive De-Risked Profile of Phase 3 Studies
Attractive De-Risked Profile of Phase 3 Studies Ocular MG Myositis MMN ITP Sjogren’s ADAPT ocular ALKIVIA EMPASSION ADVANCE Phase 3 IV domain data Proof of Concept Proof of Concept RHO and DAHLIAS Real world data Japan Proof of concept Real-world case reports Cumulative platelet count primary endpoi
Slide 25: Innovation has no value unless it provides meaningful benefit to patients
Innovation has no value unless it provides meaningful benefit to patients 25